Therapeutic modalities of deferiprone in Parkinson's disease: SKY and EMBARK studies
Open Access
- 27 December 2024
- journal article
- Published by SAGE Publications in Journal of Parkinson’s Disease
- Vol. 15 (1) , 72-86
Abstract
Background: Reducing nigrostriatal iron overload reduces neuronal loss in Parkinson's disease (PD) models. Objective: Examine the safety and efficacy of deferiprone in reducing motor disability progression in dopaminergic-treated and treatment-naïve patients with early-stage PD. Methods: Two phase II, multicenter studies, SKY and EMBARK, enrolled patients diagnosed with early PD (<3 years from screening). In SKY, patients on stable dopaminergic therapy were randomized 1:1 to one of four dosage (or placebo-matching) cohorts (300, 600, 900, 1200 mg twice daily [BID]) for 9 months. EMBARK enrolled patients on stable dopaminergic therapy or treatment-naïve patients and received 15 mg/kg BID. For both studies, the primary outcome was the change from baseline to month 9 in motor examination score (Movement Disorder Society-Unified Parkinson's Disease Rating Scale [MDS-UPDRS] Part III). ClinicalTrials.gov: NCT02728843; ANZCTR: ACTRN12617001578392. Results: Overall, 140 patients were randomized in SKY (28 per cohort). Thirty-six patients enrolled in EMBARK (27 dopaminergic-treated; 9 treatment-naïve). In the SKY study, all doses showed the same worsening as the placebo group, with the exception of the 600 mg dose, which was associated with non-significant reductions in MDS-UPDRS Part III least-squares mean (LSM) between baseline and 9 months (−2–8 points versus placebo). In EMBARK, LSM (SE) changes from baseline in MDS-UPDRS Part III were nonsignificant (–1.6 [1.7]) and significant (8.3 [3.9]) for dopaminergic-treated and treatment-naïve patients, respectively, the latter indicating disease worsening. Adverse events possibly related to deferiprone were reported in 35.7%–88.9% across all deferiprone groups vs. 42.9% for placebo. Conclusions: SKY and EMBARK studies indicate that deferiprone combined with L-dopa does not provide significant motor function benefit, while the absence of L-dopa treatment worsens symptoms.Keywords
This publication has 29 references indexed in Scilit:
- Alpha synuclein determines ferroptosis sensitivity in dopaminergic neurons via modulation of ether-phospholipid membrane compositionCell Reports, 2022
- Conservative iron chelation for neurodegenerative diseases such as Parkinson’s disease and amyotrophic lateral sclerosisJournal of Neural Transmission, 2020
- Meta‐Analysis of Copper and Iron in Parkinson's Disease Brain and BiofluidsMovement Disorders, 2019
- Iron as a therapeutic target for Parkinson's diseaseMovement Disorders, 2018
- Safety and efficacy of early start of iron chelation therapy with deferiprone in young children newly diagnosed with transfusion‐dependent thalassemia: A randomized controlled trialAmerican Journal of Hematology, 2017
- Deferiprone‐induced agranulocytosis: 20 years of clinical observationsAmerican Journal of Hematology, 2016
- Efficacy and safety of deferiprone for the treatment of pantothenate kinase-associated neurodegeneration (PKAN) and neurodegeneration with brain iron accumulation (NBIA): Results from a four years follow-upParkinsonism & Related Disorders, 2014
- Systematic review of levodopa dose equivalency reporting in Parkinson's diseaseMovement Disorders, 2010
- Metals ions and neurodegenerationBioMetals, 2007
- Movement Disorder Society‐sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS‐UPDRS): Process, format, and clinimetric testing planMovement Disorders, 2007